TMA leads the way at GCOM 2024

TMA recently returned from a high-profile week in Pittsburgh, Pennsylvania at the Global Conference on Myositis (GCOM)! Along with the almost 400 attendees for the scientific program, TMA helped lead a group of twelve worldwide patient advocacy organizations (PAOs) facilitating international collaborative efforts that included networking, sharing best practices, and brainstorming solutions to common issues….

Continue Reading
Peter Frampton, IBM, and the Rock & Roll Hall of Fame

Peter Frampton, IBM, and the Rock & Roll Hall of Fame

TMA friend Peter Frampton is nominated for the Rock & Roll Hall of Fame! Vote for Peter Frampton, legendary artist and myositis community advocate, every day at vote.rockhall.com. It’s easy to vote by providing an email address or social media handle. Voting ends on April 26! Peter’s generosity of time, influence, and resources has been…

Continue Reading

Tackling a good cause

TMA is grateful to Chelsi Boiardi and the New England Patriots for choosing our organization as the beneficiary of their My Cause My Cleats campaign.

Continue Reading

Vamorolone approved by FDA

Recently, the FDA announced the approval of a new drug, vamorolone, as a treatment for Duchenne muscular dystrophy (DMD), a genetic muscle disease that usually affects young boys. Understandably, this news hasn’t made a big splash in myositis circles, but it should. Vamorolone, marketed under the name Agamree, is a corticosteroid drug with a twist….

Continue Reading

IBM patients battle for veterans benefits

Recently, two members of TMA’s Military Veterans with Myositis Affinity Group were successful in acquiring disability benefits from the Veterans Administration. These benefits are significant. Not only are these former service members eligible to receive complete healthcare services and disability compensation, they can also access important benefits such as a travel allowance for medical appointments,…

Continue Reading